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Abstract
The immune system in patients detects and eliminates tumor cells, but tumors still progress persistently. The
mechanisms by which tumor cells survive under the pressure of immune surveillance are not fully understood. This
review is to present the evidence from clinical studies, showing a significant correlation of clinicopathological
features of carcinoma with: (1) the loss of classical human leukocyte antigen class I, (2) the up-regulation of non-
classical human leukocyte antigen class I, pro-apoptotic Fas ligand and receptor-binding cancer antigen expressed
on SiSo cells I, and (3) the formation of immunosuppressive microenvironment by up-regulation of transforming
growth factor-beta, Galectin-1, inhibitory ligand B7s, indoleamine 2,3-dioxygenase and arginase, as well as by
recruitment of tumor-induced myeloid-derived suppressor cells and regulatory T cells. All of these factors may
together protect carcinoma cells from the immune-cytotoxicity.
Introduction
Carcinoma is the most commonly type of cancer trans-
formed from epithelial cells. It has been noted for a
while that the immune-mediated spontaneous regression
of cancer occurs in patients [1]. Recent clinical studies
have demonstrated that anti-carcinoma immunity is
activated along with rise and progression of carcinoma,
indicated by: (1) the tumor-infiltrating immune cells
(TICs), including T, B and natural killer (NK) cells, are
activated [2-4], and the number of these lymphocytes
and macrophages positively correlates with cancer-speci-
fic survival rate in patients with various carcinomas
[5-7]; (2) both carcinoma antigen-specific cytotoxic T
lymphocytes (CTLs) [8-10] and antibodies [11-13] have
been identified in cancer patients; and (3) spontaneous
regression has been noted in many patients with carci-
noma cancers, in which the number of infiltrating
immune cells, including activated CD3
+ T cells, NK
cells, antigen presenting cells (APCs), is significantly
higher than that in non-regressing controls [14-16].
Therefore, the number of infiltrating immune cells
becomes a reliable biomarker for predicting cancer
relapse [17,18]. All these studies suggest that the
immune surveillance against carcinoma is active in
patients, but how carcinoma cells still can survive and
grow in some patients is not fully understood. In this
review, we attempted to summarize the evidence of
anti-immune functions of carcinoma from both clinical
and experimental studies.
Avoidance of cytotoxic lymphocyte stimulation by
attenuation of human leukocyte antigen class (HLA)
molecules
Loss of HLA class I for avoidance of CD8
+ CTL activation
Classical HLA class I constitutively expresses on epithe-
lial cells and many carcinoma cell lines, such as non-
small cell lung cancer (NSCLC) [19]. Given a central
role of HLA class I in the restriction of CD8
+ CTL
recognition of carcinoma-specific antigens, loss of HLA
class I expression undoubtedly becomes a major escape
pathway for the evasion of CD8
+ CTL surveillance, by
which any HLA class I deficient carcinoma variants can
develop to more aggressive or invasive phenotypes with-
out stimulation of primary anti-carcinoma immunity,
CD8
+ T cell response. Indeed, as listed in Table 1, the
total loss of HLA class I expression is more frequently
noted with more aggressive or metastatic stages and
poor differentiation phenotypes as compared to those
with early stages and well to moderately differentiated
lesions in patients.
A higher level of HLA class I expression in bladder
carcinoma is significantly associated with a longer
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level of HLA class I harbor more CD8
+ Tc e l l st h a n
those with altered HLA class I in renal cell carcinomas
(RCC) [30] and cervical carcinoma [31,32]. In addition,
a decrease in HLA class I expression has been noted as
early as in normal mucosa surrounding the tumor or in
situ lesion, and is significantly associated with subse-
quent development to a new primary tumor lesion
[33,34]. These data indicate that the avoidance strategy
may occur at early stages of carcinoma development,
and suggest that by loss of HLA class I expression to
avoid CD8
+ CTL seems critical for the development of
carcinoma in patients.
Heterogeneous expression of HLA class I in inactivation of
NK cell cytotoxicity
Although loss of HLA class I may benefit to carcinoma
resistance to CD8
+ CTL as discussed above, it could
increase the susceptibility to cytotoxicity of natural killer
(NK) cells [35] because HLA class I is a ligand for inhi-
bitory receptor family, killer cell immunoglobulin-like
receptor (KIR) of NK cells [36], Thus, loss of HLA class
I expression could favor the escape of antigen-depen-
dent cytotoxicity of CD8
+ C T L ,b u ta tt h es a m et i m e
carcinoma cells may become a target of NK cell cyto-
toxicity. To date, it is not completely clear how carci-
noma cells can survive under the selection of both CD8
+ CTLs and NK cells simultaneously. It has been sug-
gested that carcinoma cells find a balance between
maintenance of HLA class I expression for inhibition of
NK cell cytotoxicity and loss of its expression for the
escape from CD8
+ CTL responses. Indeed, the complete
loss of HLA class I is barely seen in carcinomas, which
may be explained by its need for inhibition of NK cell
activity. The heterogeneous losses of HLA class I either
positively or negatively correlate with carcinoma stages
or grades in patients [24,27,28], reflecting exactly the
situation of carcinoma cells; if carcinoma cancer faces
more severe cytotoxicity from NK cells versus CD8
+
CTL, certain levels of HLA class I render carcinomas
resistance to NK cells; if tumor is under the pressure of
CD8
+ CTL more than NK cells, then partial loss of
HLA class I becomes a key for survival, as indicated by
Table 1.
In addition to heterogeneous expression of HLA class
I, one has to knowledge that other strategies are seen to
avoid NK cell cytotoxicity. A clinical study with oral
squamous cell carcinomas shows that HLA class I
expression is either weak or absent for not stimulation
of CD8
+ CTL, but there is still no a clear correlation of
HLA class I expression loss with a relative proportion of
NK cells, indicating that the local factors seem to down-
regulate the final outcome of the cytotoxic immune
response of NK cells [33]. Indeed, reduced expression of
natural cytotoxicity receptor, NKG2D ligand UL16 bind-
ing protein 1 and Inter-Cellular Adhesion Molecule 1
has been seen on tumor cells [37,38], which may specifi-
cally prevent NK cell activation.
Non-classical HLA-G in inhibition of both CD8
+ CTLs and NK
cells
HLA-G is a non-classical class I antigen, originally
detected in trophoblastic cells [39], where it is proposed
to suppress maternal immune response against the
semi-allogeneic fetus. It binds to the inhibitory receptors
Ig-like transcript (ILT) 2, ILT4 or KIR2DL4, resulting in
suppression of cytotoxicity of both CD8
+ CTL and
NK cells [40,41]. The protective role of HLA-G in
Table 1 The association of deficient HLA class I expression in carcinoma with its progression in patients
Carcinoma
type
Antibodies for
immunohistochemical staining
Distribution of total HLA class I expression loss (% of negative staining*) References
Bladder W6/32 and GRH1 The altered of HLA class I including total losses associates with higher grade
lesions and tumor recurrence
[20]
A-072 1) 16.6% in G1, 38.5% in G2, and 57.1% in G3;
2) 5-year survival: 74% with positive versus 36% with negative staining
[21]
Gastric A-072 0% in T1 (mucosa & submucosa) versus100% in T2-3 (muscle and fat invasion) [22]
Esophageal W6/32 0%: normal and benign versus 40.5% carcinoma lesions [23]
Bronchogenic W6/32 and HC-10 1) 13% of Diploid versus 45% of Aneuploid;
2) 17.3% in G1-2 versus 69% in G3
[24]
NSCLC W6/32 1) 26.8% in T1-2 versus 35% in T3;
2) 20.7% in G1-2 versus 39.3% in G3; 3) 24.1% in N0 versus 34.5% in N1-2
[25]
Breast HC-10 0% in low-grade versus 67.6% in high-grade lesions [26]
W6/32 24% in primary versus 64% in corresponding LN samples [27]
Pancreatic W6/32 and 246-E8.E7 1) 6% in primary versus 43% in metastastic tumors;
2) 0% in G1, 33% in G2 and 67% in G3
[28]
Prostate A-072 1) 0% in Benign, 41% in primary and 66% in LN metastases;
2) 33% in low-grade versus 50% in high grade lesions
[29]
*The cutoff line for negative staining or total loss is 5 to 25% of cells stained with antibodies. W6/32 monoclonal antibody (mAb) detects monomorphic epitope
of HLA class I antigen (HLA-ABC); 246-E8.E7, HC-10 and GRH1 are anti-beta2-microglobulin (b2-m) mAbs; rA-270 is rabbit polyclonal anti-b2-m antibody (DAKO).
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demonstrated in many studies with patients; in contrast
to its null expression in normal epithelial cells and
benign adenomas, a high percentage (30-90%) of carci-
noma cells expresses HLA-G in a variety of cancerous
lesions, and its levels have been found to be significantly
associated with clinicopathological features and shorter
survival time of patients [42-45]. All these data indicate
that carcinoma-expressing HLA-G could be one of
important mechanisms for inhibition of both CD8
+CTL
and NK cell mediated anti-carcinoma immunity.
Induction of TIC apoptosis by expression of pro-apoptotic
ligands
Fas ligand (FasL)
FasL binding to death receptor Fas triggers apoptosis
of Fas-expressing cells including TICs. Two patterns of
FasL expression on carcinoma cells have been shown
by immunohistochemical staining: (1) up-regulation of
FasL expression on carcinoma is positively associated
with clinicopathological features in patients, shown by
that FasL expression is an early event in epithelial cell
transformation (adenoma), followed by an increase in
the percentage of FasL-expressing carcinoma cells in
high-stage or -grade lesions, and the poorer survival of
patients with high levels of FasL expression (Table 2);
and (2) high levels of FasL expression have been seen
as an independent factor for clinicopathological fea-
tures, indicated by the positive staining of persistent
FasL expression regardless of tumor stage, histologic
grade, invasion and metastasis in many studies
[47,58-61]. All of these observations suggest that FasL
expression is critical for carcinoma survival by induc-
tion of TIC apoptosis. Indeed, the pro-apoptotic func-
tion of FasL on carcinoma cells has been demonstrated
in both in vitro and in vivo; in co-cultures with a vari-
ety of carcinoma cell lines, FasL expressed on carci-
noma cells induce apoptosis of lymphocytes in
Fas-dependent manner [49,51,62-66], and in carcinoma
biopsies from patients, the present of FasL on carci-
noma cells is in parallel with apoptosis of TICs
[53,60,67-69] or reduced number of TICs [70,71].
In the experimental studies with animal models, down-
regulation of FasL expression in carcinoma signifi-
cantly reduces tumor development in syngeneic
immunocompetent mice [72], while persistent expression
of Fas enhances tumor growth along with an increase in
lymphocyte apoptosis [73,74], and is acquired for survival
from active specific immunotherapy [75].
Receptor-binding cancer antigen expressed on SiSo cells
(RCAS) 1
RCAS1 is a recently characterized human tumor-
associated antigen expressed in a wide variety of cancer
tissues, and induces cell cycle arrest and/or apoptosis in
RCAS1 receptor-expressing immune cells. Like FasL on
carcinoma cells, RCAS1 is expressed in a high percen-
tage of carcinoma cells (30-100%) and is significantly
correlated with clinicopathological features including a
shorter survival time for patients, and with apoptosis or
reduction of TICs [76-81]. In co-cultures of interleukin
(IL)-2 activated peripheral blood lymphocytes with
human oral squamous cell carcinomas cell line (KB
cells), lymphocyte apoptosis is associated with the pre-
sence of soluble RCAS1 in the medium [77]. In addition,
Table 2 FasL expression in carcinoma cancers
Carcinoma type Distribution of high FasL expression References
Colorectal 19% in adenomas, 40% of stage I-II, 67% of stage III and 70% of stage IV of carcinoma [46]
40.9% in adenoma versus 80.8% in carcinoma [47]
Higher incidence of metastases and poorer patients’ survival associate with FasL positive carcinomas [48]
0 positive in normal epithelial cells, 2/7 positive in primary tumors, 4/4 positive in hepatic metastatic tumors [49]
Adrenocortical 37.7% in adenomas versus 100% in the carcinoma [50]
Bladder transitional cell 1) 0% in normal urothelium, 0% in G1, 14% in G2, and 75% in G3.
2) 13% in superficial Ta-T1 versus 81% in invasive T2-T4
[51]
0% in normal urothelium, 19% in T1, 21% in T2 and 49% in T3 [52]
Pancreatic ductal 1) 82% in primary versus 100% in hepatic metastases
2) Shorter survival for patients associates with FasL positive tumors
[53]
Nasopharyngeal 1) 0% in stage I, 57% in stage II, 58% in stage III and 82% in stage IV;
2) A lower rate of disease-free and overall survival for patients associates with positive FasL expression.
[54]
Gastric 36.2% in adenomas, 68.8% in early carcinoma, and 70.4% in advanced carcinoma [55]
Cervical 1) 5/14 in inner 2/3 stromal invasion versus 10/10 outer 2/3 stromal invasion;
2) 7/15 without LN metastasis versus 8/9 with LN metastasis;
3) Reduced survival times in patients with FasL-expressing tumors
[56]
Esophageal 1) Higher incidence of LN metastasis associates with the tumors containing >25% FasL expression;
2) All cancer metastases in LN express FasL in >50% of the cells
[57]
LN: lymph nodes.
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RCC promotes lymphocyte apoptosis by binding to its
receptor CD27, indicating a proapoptotic role of CD70
in the elimination of TICs as well [82]. All these obser-
vations suggest that the direct induction of TIC apopto-
sis by persistent expression of FasL, RCAS1 or perhaps
other apoptosis-inducing ligands (e.g. CD70) on carci-
noma cells plays a role in the ability of carcinoma cells
to escape from the anti-carcinoma immunity.
Suppression of TIC activity by molecular and cellular
factors
Immunoregulatory cytokine/cytokine-like: Transforming
growth factor (TGF)-b1 and Galectin-1 (Gal-1)
TGF-b1 is a multifunctional cytokine involved in immu-
nosuppression. Numerous clinical studies have demon-
s t r a t e dt h a tah i g h e rl e v e lo fT G F - b1 expression is
significantly associated with an invasive phenotype of
tumors or metastases in patients [83-86]. In vitro a sig-
nificant amount of TGF-b1i sp r o d u c e di nt h ep o o r l y
differentiated prostate carcinoma cell lines but not in
well-differentiated cells [87]. These data imply that
TGF-b1 may increase metastasis by a paracrine matter,
such as suppression of local immune response or
increased angiogenesis. Indeed, in the biopsies of cervi-
cal carcinoma tumors, an inverse relationship between
TGF-b1 expression in tumor cells and the extent of
TICs is demonstrated [88]. This clinical observation is
further confirmed by several experimental studies. In a
mouse skin explant model, TGF-b1 is produced by pro-
gressor types but not regressor squamous cell carcinoma
lines, and this tumor-derived cytokine inhibits migration
of professional APCs, Langerhans cells (LCs), and keeps
them in an immature form [89], or transgenic expres-
sion of TGF-b1 enhances growth of regressor squamous
carcinoma cells in vitro and in vivo just like progressor
phenotype, and reduces the number of infiltrating LCs,
CD4
+ and CD8
+ T cells [90]. A further study with inva-
sive colon carcinoma U9A cell line shows that decreas-
ing TGF-b1 expression by antisense reduces the invasive
activity and metastasis of tumor cells to the liver [91].
All these studies suggest that carcinoma-derived TGF-b
plays an important role in the tumor metastasis, which
may be caused by its immune suppressive function.
Gal-1 is a member of b-galacosidess binding protein
family (galectins), and is a recently identified immunore-
gulatory cytokine-like molecule in cancer [92]. It has
been documented that Gal-1 exhibits immunoregulatory
effects by which it controls immune cell trafficking, reg-
ulates activation of dendritic cells (DCs) and induces
T-cell apoptosis [93]. Up-regulation of Gal-1 expression
has been seen in a variety of carcinoma biopsies, parti-
cularly in tumor-associated stroma, and is associated
with tumor invasiveness or worse prognoses [94-97] and
with reduced infiltrating T cells [98], suggesting that
Gal-1, produced by carcinoma and/or stromal cells sur-
rounding the tumor, may take a part in the carcinoma
immune-escape by regulation of T cell homeostasis.
This hypothesis is supported by a recent study showing
that tumor cell-expressing Gal-1 induces T cell apopto-
sis in a co-culture system [99].
Immune inhibitory ligands: B7 family members (B7-H1, -H3
and -H4)
B7-H1 (PD-L1) is a ligand for the receptor PD-1 on
T cell, and is known to negatively regulate T-cell activa-
tion [100]. Similar to B7-H1, B7-H3 or -H4 ligation of
T cells has a profound inhibitory effect on Th1 differen-
tiation [101], as well as the proliferation, differentiation
and cytotoxicity of T cells [102]. Over-expression of
these B7 family members (B7-H1, -H3 or -H4) has been
documented in various types of carcinoma as compared
to healthy controls: (1) H7-H1 in pancreatic tumors
[103,104], RCC [105,106], human hepatocellular carci-
noma (HCC) [107,108], urothelial cell carcinoma (UCC)
[109] and NSCLC [110]; (2) B7-H3 in UCC [111]; and
(4) H7-H4 in NSCLC [112], breast cancer [113,114] and
ovarian cancer [115]. Tumor B7-H1 expression is
significantly associated with less TICs including PD-1
positive immune cells, poor tumor differentiation,
advanced tumor stage and poorer survival of patients
[103,104,106-110,115]. Similar correlation of B7-H4 with
clinicopathological features has been reported as
well [111-114].
In parallel with up-regulation of B7-H1, the number of
PD-1
+ CD8
+ cells increases in tumor tissues, such as HCC
[108,116] and prostate cancer [117], and these tumor-
infiltrating CD8
+ cells have been shown to be impaired in
the granule and cytokine productions [108,117-119]. In
addition, blocking the interaction of B7-H1 with PD-1
using neutralizing antibody restores the effector function
of tumor-infiltrating T cells [108,119] and in a mouse
model of pancreatic cancer, the antibody therapy,
combined with gemocitabine, induces a complete regres-
sion of tumor growth [104]. All these studies indicate that
up-regulation of B7 inhibitory molecules acts as an immu-
nosuppressive strategy for carcinoma to escape from anti-
carcinoma immunity during cell-cell contact with T cells.
Depletion of amino acids enzymes: indoleamine 2,3-
dioxygenase (IDO) and arginase (ARG)
The mechanisms by which IDO induces immunosuppres-
sion have been recently reviewed [120]. IDO is a trypto-
phan-catabolising enzyme. Up-regulation of its synthesis
has been documented in IFN-g-stimulated cultures of KB
oral carcinoma and WiDr colon adenocarcinoma [121],
pancreatic carcinomal cells [122], hepatocellular carci-
noma cell lines [123], and colorectal carcinoma cell lines
[124]. Over-expression of IDO protein is reported in the
cancerous lesions, and significantly correlates with
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with a variety of carcinoma cancers [122-126]. The up-
regulation of IDO is associated with a significant reduction
of CD3
+ TICs [124], or with an increased number of regu-
latory T (Treg) cells in the metastatic carcinoma in lymph
nodes (LNs) [122]. Ectopic expression of IDO enhances
tumor growth of the human endometrial carcinoma cell
line AMEC and suppresses cytotoxicity of NK cells in a
mouse xenograft model [127]. All these observations sug-
gest that IDO-high expression in carcinoma cells in pri-
mary tumors may defeat the invasion of effector T cells
and NK cells via local tryptophan depletion as well as pro-
duction of proapoptotic tryptophan catabolites. Also, IDO
in metastatic carcinoma cells may enhance the differentia-
tion of Treg cells as a potent immunosuppressive strategy.
ARG is an arginine-metabolic enzyme converting
L-arginine into L-ornithine and urea [128]. It has been
suggested that arginine is one of essential amino acids
for T cell activation and proliferation [129], and the
depletion of extracellular arginine by ARG results in the
modulation of CD3ζ chain expression and proliferative
suppression in T cells [130]. A significantly high level of
ARG activity has been demonstrated in the carcinomas
of the prostate [131], the gallbladder [132] and the lung
[133,134], but the evidence for the contribution of ARG
activity to tumor immune escape is still weak; ARGII
and NOSII together has been shown to participate in
local peroxynitrite dependent immune suppression of
prostate cancer [135], but not seen in lung cancer [136].
H o w e v e r ,t h i se n z y m em a yp l a yac r i t i c a lr o l ei nt h e
immunosuppressive activity of tumor-induced myeloid-
derived suppressor cells (MDSCs) as discussed below.
Immunosuppressive cells: CD4
+CD25
+Foxp3
+ regulatory
T (Treg) cells and Tumor-induced myeloid-derived
suppressor cells (MDSCs)
Treg cells can inactivate both effector/helper T and B
cells. After activation, Treg cells not only produce abun-
dant anti-inflammatory cytokine IL-10 and TGF-b,b u t
also express cell surface CTLA-4, which binds to B7
molecules on APCs, resulting in suppression of effector
T cells and their dependent B cells. Numerous studies
with cancer patients have demonstrated that the preva-
lence of Treg cells is significantly high in cancerous
lesions as compared to those in healthy controls
[136-141], and the percentage of Treg cells among TICs
positively correlates with a significantly lower survival
rate [138,139,142]. In mice challenged with pancreas
adenocarcinoma cells (Pan02), depletion of Treg cells
promotes a tumor-specific immune response, and signif-
icantly associates with smaller size of tumor and longer
survival [143]. All these studies suggest that an increase
in Treg cells in TICs may play a central role in self-
tolerance to carcinoma cells, which may “hijack” these
Treg cells as an effective strategy for immunoescape by
suppression of anti-carcinoma immunity.
However, the mechanism of elevation of Treg cells in
TICs is not fully clarified, but may be due to their local
proliferation/differentiation or recruitment from circula-
tion to cancerous lesion or to both. Indeed, the presence
of Treg cells in carcinoma lesions is in conjunction with
immature DCs, Th2 cytokine dominant microenviron-
ment, prostaglandin E2 (PGE2) and IDO activity
[122,144,145] or is required the function of CCL22
[146] and/or CCL5 [147]. Chemokine CCL22 and CCL5
mediate trafficking of Treg cells to the tumors, whereas
immature DCs, Th2 cytokines and PGE2 favor Treg cell
proliferation and/or differentiation.
MDSCs represent a heterogeneous population of
immunosuppressive cells expressing a variety of surface
markers, such as CD11c
+,C D 1 1 b
+,C D 3 3
+,C D 3 4
+ and
CD15
+. In patients with all different types of carcino-
mas, an increasing number of MDSCs have been found
in peripheral blood [148-150] and/or intratumor lesions
[151-153]. The frequency of these cells also positively
correlates with the incidence of recurrence or metastatic
disease in patients [153,154]. Experimental studies show
that MDSCs can function as potent suppressors of cyto-
toxicity of both effector CD8
+ T-cells [155] and NK
cells [156]. The immunosuppressive activities of MDSCs
may depend on the activity of ARG and/or reactive oxy-
gen species they produce [150,157,158] or the induction
of Foxp3
+ Treg cells [159]. All these studies suggest that
MDSCs may be one of important factors responsible
not only for systemic immune dysfunction in cancer
patients but also for local carcinoma immune escape.
Conclusions
The evidence from the limited literature we reviewed
clearly indicates that carcinoma development in
patients closely correlates to its ability to inactivate
effector cytotoxic lymphocytes (i.e. CD8
+ CTL and NK
cells), to induce TIC apoptosis and/or to suppress the
anti-carcinoma immune response, as indicated by:
(1) down-regulation of antigen-presenting protein HLA
class I; (2) up-regulation of immunosuppressive pro-
teins, such as cell surface FasL, HLA-G, immune inhi-
bitory ligand B7 family members, secreted cytokine
TGF-b and Gal-1, enzyme IDO and perhaps ARG, and
(3) induction/expansion of immunosuppressive cells:
MDSCs and/or Foxp3
+ Treg cells (Figure 1). Thus, it
must be acknowledged that carcinoma develops multi-
ple adaptation mechanisms against immune surveil-
lance, but different types of carcinoma cancer may use
different anti-immune strategies depending on the
spectrum of host anti-carcinoma immunity in patients.
Further understanding of these mechanisms by which
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lead to develop more effective immunotherapyi
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